Skin substitute (CTP)

A skin substitute, also called a cellular and tissue-based product (CTP), is a wound care product used to support healing of chronic and surgical wounds. CTPs include amniotic and chorionic membrane products, cellular bilayer skin equivalents, acellular dermal matrices, and synthetic and biosynthetic preparations. CTPs are billed to Medicare and other payors using Q-series HCPCS codes (Q4100 and following). The Apex Medical $309M False Claims Act settlement and the CMS 2026 reclassification under the WISeR Model placed CTPs at the center of wound care enforcement.

How skin substitute billing and enforcement work

CTPs are dispensed and applied in wound care clinics, ambulatory surgical centers, and hospital outpatient settings. The provider documents the wound's characteristics (depth, area, duration, comorbidities), the medical necessity for CTP use, the specific product applied, and the application sequence. Each application generates a claim under the relevant Q-code with the corresponding CPT application code. Medicare pays at the published Average Sales Price (ASP) plus add-on percentage; commercial payors vary.

CMS reclassification under the 2026 WISeR Model (Wasteful and Inappropriate Service Reduction) moved many CTPs to prepayment review, which suspends payment on every new claim until medical necessity is documented. The CMS prepayment review framework operates in parallel with the existing UPIC and RAC postpayment review tracks. The Apex Medical $309M FCA settlement established the enforcement template that subsequent qui tam matters have followed.

When skin substitute enforcement applies

Skin substitute enforcement applies to wound care providers (podiatry, dermatology, vascular surgery, plastic surgery, primary care), wound care clinics, ambulatory surgical centers, and the manufacturers and distributors that supply CTPs. Both prepayment review (CMS WISeR Model) and postpayment audit (UPIC, RAC) track the high-dollar CTP claim universe. False Claims Act exposure surfaces through qui tam relators, often former clinic staff or competing providers who observed billing patterns.

The provider's exposure under skin substitute enforcement

Recoupment exposure on individual CTP claims can run from $1,000 to $20,000 per application; statistical extrapolation across a multi-year claim universe produces six- and seven-figure demands. Cash-flow exposure under prepayment review halts CTP-claim payment until medical necessity is documented. FCA exposure runs through treble damages and per-claim penalties; the Apex Medical $309M template demonstrated that pattern recoveries can reach nine figures. The defense framework focuses on medical necessity documentation, application-frequency justification, billing accuracy, and the methodology challenge where statistical extrapolation scales the exposure.

Related terms

• Debridement The parallel wound care service category that often runs alongside CTP application in audited matters.
• False Claims Act The civil statute under which most CTP enforcement runs.
• UPIC The CMS contractor that conducts most CTP postpayment review.
• Extrapolation The statistical technique that scales CTP findings across the claim universe.

See also

• Practice area
  Skin Substitute FCA Defense

  The full skin substitute defense framework in the post-Apex enforcement wave.

• Practice area
  Wound Care Audit Defense

  The wound care audit defense pillar covering CTP, debridement, and prepayment review.